{"filing":{"accession_number":"0001104659-26-074853","cik":"0001590560","ticker":"QURE","company_name":"uniQure N.V.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"tm2618105d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926074853/tm2618105d1_8k.htm"},"events":[{"id":11436,"run_id":10040,"accession_number":"0001104659-26-074853","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8025,"accession_number":"0001104659-26-074853","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:11:06.570556+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8025,"accession_number":"0001104659-26-074853","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:11:06.570556+00:00","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-06-17"}]}